Teva Pharmaceutical Industries Q1 Earnings: AUSTEDO Surges as Teva Plots $700M Emalex Buyout

3 weeks ago 18

MarketBeat

Mon, May 4, 2026 astatine 4:43 AM CDT 6 min read

Teva Pharmaceutical Industries logo

MarketBeat Week successful Review – 02/03 - 02/07

Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that absorption said bespeak continued execution of its “Pivot to Growth” strategy, portion besides detailing a planned acquisition designed to grow its neuroscience portfolio.

Q1 results: Innovative portfolio maturation offsetting expected generics unit

Chief Executive Officer Richard Francis said the institution “had a bully commencement to the year,” with show “driven by continued spot of our innovative portfolio.” Teva reported gross of $4.0 cardinal for the quarter, down 1% versus the anterior twelvemonth period, portion adjusted EBITDA roseate 2% to $1.1 cardinal and non-GAAP EPS accrued to $0.53. Free currency travel grew 76% to astir $200 million, and nett indebtedness to EBITDA was 2.42, Francis said, comparing results to Q1 2025.

→ 5 Stocks to Buy successful May Before the Next AI Surge Hits

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

Francis emphasized that results were aligned with expectations fixed the anticipated diminution successful generic Revlimid revenue. Excluding some the Japan divestment and generic Revlimid, helium said gross was up 7%.

Teva’s cardinal innovative products continued to station beardown year-over-year growth. Francis said the company’s innovative portfolio grew 41% successful the quarter, driven by:

AUSTEDO: up 41% to $578 cardinal (U.S. gross $559 million), with 13% TRx maturation and 20% milligram growth; AUSTEDO XR represented much than 60% of caller patients.
AJOVY: up 35% to $196 million, with maturation driven by the U.S. and Europe, including market-share gains and improved access.
UZEDY: up 62% to $63 million, with underlying TRx maturation of 75%.

→ Bloom Energy May Be Solving AI’s Biggest Power Problem

2 Generic Drug Stocks Ready to Surge successful 2025

On AUSTEDO, Francis reiterated full-year guidance of $2.4 cardinal to $2.55 cardinal successful revenue. He besides noted that transmission inventory built successful Q4 was “not each been drawn down successful Q1,” a dynamic CFO Eli Kalif said benefited Q1 gross and could power quarterly progression. Kalif added that Teva continues to expect AUSTEDO gross successful Q4 2026 to beryllium down year-over-year owed to purchasing and pricing dynamics up of IRA implementation successful January 2027.

Emalex acquisition: Ecopipam aimed astatine Tourette syndrome unmet request

Management devoted important clip to Teva’s statement to get Emalex Biosciences, which Francis described arsenic the company’s “first acquisition nether the Pivot to Growth strategy.” The woody would bring ecopipam, which Francis called a “first-in-class plus with compelling efficacy and favorable tolerability successful Tourette syndrome.” He characterized Tourette syndrome arsenic a “serious life-altering pediatric neurological upset with constricted bully options today,” arguing that existent therapies often unit tradeoffs betwixt efficacy and tolerability.

Read Entire Article